InvestSMART

Argenica Therapeutics Limited (ASX:AGN)

ALERT: Price-sensitive ASX Announcement for AGN
Current share price for AGN : $0.120 -0.08 (-40%)+
Announcement
Release
17 Mar 2026 8:19AM
Price at Release
$0.200
Full Release
download
Summary
Argenica Therapeutics Limited announced the receipt of a $3.97 million cash rebate from the Australian Federal Government's R&D Tax Incentive Program for the financial year ending on June 30, 2025. This rebate, which includes newly approved overseas activities, boosts the company's proforma cash balance to $9 million as of December 31, 2025. The funds will support the development of their lead neuroprotective peptide candidate, ARG-007, which is being advanced for a Phase 2b acute ischemic stroke trial. This initiative underscores the support for Australian innovation through the R&D Tax Incentive Program.
Key Points
  • Argenica receives $3.97m R&D Tax Incentive cash rebate for FY25.
  • Rebate includes newly approved overseas activities.
  • Proforma cash balance of $9.0m as of December 31, 2025.
  • Funds to advance development of ARG-007 for Phase 2b AIS trial.
  • R&D Tax Incentive Program supports Australian innovation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.